XIRP2

Across TCGA pan-cancer cohorts, XIRP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated XIRP2 data layer compared with 21 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher XIRP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated XIRP2 expression acts as an unfavorable survival marker.

PDAC, LSCC, and HNSC are the cancer types where XIRP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.703	0.938	.006	13	view →
LSCC	DFS	Quartile	II,III,IV	0.394	1.000	.009	9	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

XIRP2–PDAC (DFS)

Open the PDAC breakdown →